Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University scientists carry out clinical trials for a range of medical conditions every year. The hope with each one is that it could lead to a viable treatment to cure or alleviate that condition. It is easy, therefore, to think that a successful trial is one that produces such a treatment, while any other result is a failure. Not so, as a recent study from Oxford's researchers in South East Asia shows.

Culture of yeast following brain fungal infections

Similar stories

First-of-its-kind study found equine antitoxin is safe and effective for the treatment of tetanus in adults

A first-of-its kind randomised controlled trial compared two different antitoxin treatments for tetanus. A comparison of human and equine intramuscular antitoxin in adults found that intramuscular equine antitoxin is safe and effective for treating tetanus in adults. Addition of additional intrathecal (spinal) antitoxin does not add any benefit compared to treatment with intramuscular antitoxin alone.

Picturing Health: The Burden of Leprosy in Eastern Indonesia

The Eijkman Oxford Clinical Research Unit in Indonesia and Sumba Foundation collaborated with photographer Yoppy Pieter to express the human face of leprosy in Sumba, a remote island in eastern Indonesia. The project aimed to visualize the story of leprosy and raise awareness of this debilitating and heavily stigmatised disease

Research Culture at OUCRU

What do we mean by 'Research Culture' and how has fostering a multinational, collaborative culture helped us deliver world-class research? Let's explore the research culture at OUCRU.

Policy and Public Engagement at OUCRU

Why does OUCRU place an important focus on engaging with its important partners, policy makers, the press, the community, and young people? Explore our work in policy & public engagement.

World TB Day 2022: Invest to End TB. Save Lives

Each year on 24 March, World TB Day is commemorated to raise awareness of this devastating and deadly disease. The theme for this year’s World TB Day is “Invest to End TB. Save Lives”, conveying the urgent need to invest resources to ramp up the fight against TB and achieve the commitments to end TB made by global leaders.

TACT-CV study shows artemether–lumefantrine plus amodiaquine an effective treatment for multidrug-resistant malaria in GMS

A triple artemisinin-based combination therapy (TACT) of artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance is a well-tolerated, effective treatment for multidrug-resistant parasites, say a team of MORU-led researchers.